Effect of High-Flow Nasal Cannula Oxygen Therapy in Immunocompromised Subjects With Acute Respiratory Failure.

BACKGROUND: Various studies have been performed to examine the effect of high-flow nasal cannula (HFNC) in immunocompromised patients with acute respiratory failure (ARF). However, the results were inconsistent. Thus, we conducted a meta-analysis to evaluate the effect of HFNC oxygen therapy in immu...

Descripción completa

Detalles Bibliográficos
Publicado en:Respiratory Care Vol. 65; no. 3; pp. 369 - 377
Autores principales: Hanyujie Kang, Zhiling Zhao, Zhaohui Tong
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Mar2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141940025&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 141940025
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00201324
        4GG
      jtl: Respiratory Care
      issn: 00201324
      maglogo: N
    pubinfo:
      dt: Mar2020
      vid: 65
      iid: 3
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        141940025
        141940025
        141940025
        10.4187/respcare.07205
        141940025
      ppf: 369
      ppct: 8
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Effect of High-Flow Nasal Cannula Oxygen Therapy in Immunocompromised Subjects With Acute Respiratory Failure.
      aug:
        au:
          Hanyujie Kang
          Zhiling Zhao
          Zhaohui Tong
        affil: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao- Yang Hospital, Capital Medical University, Beijing, China
      sug:
        subj:
          Nasal Cannula
          Noninvasive Procedures
          Immunocompromised Host
          Respiratory Failure Therapy
          Oxygen Therapy Methods
          Respiration, Artificial
          Human
          Systematic Review
          Meta Analysis
          Funding Source
          Intubation
          Hospital Mortality
          Cross Infection
          Confidence Intervals
          Descriptive Statistics
          PubMed
          Embase
          Cochrane Library
          Respiratory Failure Prognosis
      ab: BACKGROUND: Various studies have been performed to examine the effect of high-flow nasal cannula (HFNC) in immunocompromised patients with acute respiratory failure (ARF). However, the results were inconsistent. Thus, we conducted a meta-analysis to evaluate the effect of HFNC oxygen therapy in immunocompromised patients with ARF versus conventional oxygen therapy and noninvasive ventilation (NIV). METHODS: Relevant studies published prior to May 11, 2019, were systematically searched. The primary outcome was intubation rate; secondary outcomes were mortality (ICU mortality, in-hospital mortality, and 90-d mortality) and ICU-acquired infections. Data were pooled using the random effects model. RESULTS: Of 832 identified studies, 8 were eligible for inclusion in our analysis (N = 2,167 subjects). HFNC was associated with lower intubation rates compared to conventional oxygen therapy (risk ratio [RR] 0.89, 95% CI 0.79 -1.00, P = .040), but we found no significant difference in the rate between HFNC and NIV (RR 0.74, 95% CI 0.46-1.19, P = .22). We also found that HFNC did not increase the risk of ICU-acquired infections (RR 0.86, 95% CI 0.63-1.18, P = .35). However, in comparison to other noninvasive therapies, HFNC exhibited no differences in ICU mortality (RR 0.82, 95% CI 0.58 -1.17, P= .28), in-hospital mortality (RR 0.92, 95% CI 0.74 -1.15, P= .48), or 90-d mortality (RR 0.98, 95% CI 0.81-1.18, P=_ .82). CONCLUSIONS: Our results suggest that HFNC may be a feasible alternative to NIV, with lower intubation rates and no increased risk for ICU-acquired infections compared to standard oxygen therapy. However, HFNC did not appear to reduce mortality in immunocompromised subjects with ARF compared with other noninvasive therapies. Further high-quality randomized controlled trials should be performed to confirm these findings.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N